OncoMatch/Clinical Trials/NCT05709249
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Is NCT05709249 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies XLJDOD compound granule for colon cancer.
Treatment: XLJDOD compound granule — This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgical resection
Completion of surgical resection of tumors with negative margins (R0 resection)
Must have received: adjuvant chemotherapy (5-fluorouracil, capecitabine, oxaliplatin, leucovorin) — adjuvant
at least 3 months of adjuvant chemotherapy based on 5-fluorouracil (5-FU). 4 cycles of CAPOX (capecitabine and oxaliplatin), 6 cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or 4 cycles of single agent-5-FU, etc.
Cannot have received: adjuvant radiotherapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: adjuvant targeted therapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: adjuvant immunotherapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: antitumor Chinese patent medicine and decoction
Antitumor Chinese patent medicine and decoction have been used for more than 3 months after surgery or within 1 month before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify